Trial Profile
A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Anal cancer
- Focus Therapeutic Use
- 17 May 2023 Status changed from active, no longer recruiting to completed.
- 27 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 12 May 2021 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.